Back to Search Start Over

A double-blind, double-dummy, randomized controlled, multicenter trial of 99Tc-methylene diphosphonate in patients with moderate to severe rheumatoid arthritis

Authors :
Qiong Fu
Ping Feng
Ling-Yun Sun
Xiao-Xia Zuo
Dong-Bao Zhao
Dong-Yi He
Hua-Xiang Wu
Wei Zhang
Fang Du
Chun-De Bao
Li-Shao Guo.
Source :
Chinese Medical Journal, Vol 134, Iss 12, Pp 1457-1464 (2021)
Publication Year :
2021
Publisher :
Wolters Kluwer, 2021.

Abstract

Abstract. Background:. Clinical observational studies revealed that 99Tc-methylene diphosphonate (99Tc-MDP) could reduce joint pain and swollenness in rheumatoid arthritis (RA) patients. This multicenter, randomized, double-blind, double-dummy study aimed to evaluate the effects of 99Tc-MDP plus methotrexate (MTX) vs. MTX alone or 99Tc-MDP alone on disease activity and structural damage in MTX-naïve Chinese patients with moderate to severe RA. Methods:. Eligible patients with moderate to severely active RA were randomized to receive 99Tc-MDP plus MTX (n = 59) vs. MTX (n = 59) alone or 99Tc-MDP (n = 59) alone for 48 weeks from six study sites across four provinces in China. The primary outcomes were the American College of Rheumatology 20% improvement (ACR20) response rates at week 24 and changes in modified total Sharp score at week 48. Results:. At week 24, the proportion of participants achieving ACR20 was significantly higher in the MTX + 99Tc-MDP combination group (69.5%) than that in the MTX group (50.8%) or 99Tc-MDP group (47.5%) (P = 0.03 for MTX + 99Tc-MDP vs. MTX, and MTX + 99Tc-MDP vs.99Tc-MDP, respectively). The participants in the MTX + 99Tc-MDP group and the 99Tc-MDP group had significantly less important radiographic progression than the participants in the MTX group over the 48 weeks (MTX + 99Tc-MDP vs. MTX: P = 0.03, 99Tc-MDP vs. MTX: P = 0.03, respectively). There was no significant difference in terms of adverse events (AEs) among the groups. No serious AEs were observed. Conclusions:. This study demonstrated that the combination of 99Tc-MDP with MTX inhibited structural damage and improved disease activity in RA patients compared with MTX and 99Tc-MDP monotherapies, without increasing the rate of AEs. Additional clinical studies of 99Tc-MDP therapy in patients with RA are warranted. Trial Registration:. Chictr.org, ChiCTR-IPR-14005684; http://www.chictr.org.cn/showproj.aspx?proj=10088.

Subjects

Subjects :
Medicine

Details

Language :
English
ISSN :
03666999, 25425641, and 00000000
Volume :
134
Issue :
12
Database :
Directory of Open Access Journals
Journal :
Chinese Medical Journal
Publication Type :
Academic Journal
Accession number :
edsdoj.0154d708632476ea9faff729426fb6b
Document Type :
article
Full Text :
https://doi.org/10.1097/CM9.0000000000001527